Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$216.00 USD

216.00
308,627

+0.93 (0.43%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (168 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Exact Sciences' (EXAS) Q2 Earnings Beat, Margin Declines

by Zacks Equity Research

Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q2 earnings.

Chemed (CHE) Q2 Earnings Beat Estimates, Margins Decline

by Zacks Equity Research

Chemed (CHE) witnesses solid revenue growth across key subsidiaries in Q2 earnings.

CONMED (CNMD) Q2 Loss Narrower Than Expected, Revenues Top

by Zacks Equity Research

CONMED's (CNMD) core units - General Surgery and Orthopedic Surgery - witnessed revenue decline in Q2.

Merit Medical (MMSI) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Merit Medical (MMSI) reported a drop in revenues at every key operating segment in Q2.

Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Hologic (HOLX) exhibited robust segmental growth in third-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Baxter (BAX) Earnings and Revenues Miss Estimates in Q2

by Zacks Equity Research

Baxter's (BAX) second-quarter earnings reflect weak performance across Medication Delivery, Pharmaceutical and Advanced Surgery business units and contraction in margins.

Cerner (CERN) Q2 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Cerner (CERN) second-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in margins.

Boston Scientific (BSX) Q2 Earnings Top, Margins Decline

by Zacks Equity Research

This time too Boston Scientific (BSX) refrains from providing any update on the full-year guidance.

Amedisys (AMED) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

Amedisys' (AMED) second-quarter results reflect impressive performance by the Hospice division despite pandemic-led challenges.

Omnicell (OMCL) Q2 Earnings Lag Estimates, Margins Down

by Zacks Equity Research

Omnicell's (OMCL) second-quarter revenues suffered due to slowdown in hospital purchasing decisions and product bookings owing to pandemic-led business disruptions.

LabCorp (LH) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

LabCorp (LH) Beats Q2 Earnings Estimates, Margins Decline

by Zacks Equity Research

LabCorp (LH) witnesses a 20.7% decline in organic volume, partially offset by acquisition volume growth of 1.2%.

Is Laboratory Corporation of America Holdings (LH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (LH) Outperforming Other Medical Stocks This Year?

LabCorp (LH) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

LabCorp (LH) delivered earnings and revenue surprises of 229.49% and 14.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Delayed Orders Hurt Ekso Bionics (EKSO) Q2 Earnings?

by Zacks Equity Research

Ekso Bionics (EKSO) Q2 earnings are expected to have been boosted by its recent efforts to grow virtual connectivity with customers and to reduce costs.

Zynex (ZYXI) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Zynex's (ZYXI) April orders down approximately 35% from the January and February average. This may have impacted its Q2 earnings.

Why Earnings Season Could Be Great for LabCorp (LH)

by Zacks Equity Research

LabCorp (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What's in Store for IDEXX Laboratories (IDXX) in Q2 Earnings?

by Zacks Equity Research

IDEXX's (IDXX) top line is likely to have benefited from a robust CAG business and regulatory approvals for its COVID-19 tests.

Zacks.com featured highlights include: Plains GP, Principal Financial Group, Laboratory Corporation of America, Korea Electric Power and Piedmont Office Realty Trust

by Zacks Equity Research

Zacks.com featured highlights include: Plains GP, Principal Financial Group, Laboratory Corporation of America, Korea Electric Power and Piedmont Office Realty Trust

Bio-Rad (BIO) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Strength in product demand related to COVID-19 testing and research is likely to have aided Bio-Rad's (BIO) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.

LH vs. ALGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

LH vs. ALGN: Which Stock Is the Better Value Option?

Here's Why You Should Add AMN Healthcare to Your Portfolio

by Zacks Equity Research

Investor confidence is high in AMN Healthcare (AMN) stock, thanks to solid prospects.

Anindya Barman headshot

Tap These 5 Bargain Stocks With Alluring EV-to-EBITDA Ratios

by Anindya Barman

We have screened bargain stocks based on EV-to-EBITDA ratio that offers a clearer picture of a company's valuation and earnings potential.

ViewRay (VRAY) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Strength in MRIdian system business is likely to have aided ViewRay's (VRAY) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.

Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.